ALZHEIMERS
NKGen – by serendipity treated Alzheimer’s Disease (AD) patients with large intravenous doses of patients own NK cells – remarkable response – went on to show >90% patient response rate in AD patients. Effective but very costly and time consuming – treating 3 weekly for 3-4 months. No evidence that NK cells get into the brain.
At Cartherics Pty Ltd, we developed NK cells for cancer therapy and discovered they release tiny particles called extracellular vesicles (or exosomes) that may help treat Alzheimer’s disease. These vesicles can activate the brain’s immune cells to clear amyloid plaques, reduce inflammation, and potentially reduce tau tangles. Because they are not rejected by the immune system, they could be delivered as a simple nasal spray directly to the brain (non-invasive). They are also inexpensive to produce, with each dose potentially costing only tens of dollars.
There are strong clinical interests for early clinical studies
The potential therapy and confirmation of safety is being tested in mice and AD dogs (similar to human AD)
A major Pharma Company has helped Evinco plan the proof-of-concept studies.
A US VC has expressed interest in funding Evinco when we have proof of concept (expected in 12-18 months)
The NK-EV product can also be used to treat traumatic brain injury - global cost US$1.1 Trillion/year with no treatment available. Strong interests from TBI researchers and clinicians to trial the Evinco product
Evinco is seeking $2M for the preclinical research and operations for establishing this potential therapy. We expect that we could be treating AD or TBI patients in exploratory studies within 18 months.
RESEARCH COMPANY
Evinco is the company with the breakthrough opportunity for neurological repair – particularly Alzheimer’s Disease and Traumatic Brain Injury.
Its role is to hold, progress, protect and commercialise the research pathway through the correct funding, licensing and development structure.
The immediate requirement is to secure the next phase so the opportunity can be advanced properly.
HOW IT ALL STARTED
Like many scientific breakthroughs, Evinco Therapeutics was born from an unexpected discovery.
While investigating the therapeutic potential of natural killer (NK) cells, Evinco's founders observed something remarkable: the extracellular vesicles (EVs) released by these cells appeared to have a profound effect on neuroinflammation and on amyloid plaque clearance by the brain immune cells - microglia, two of the key drivers of neurodegenerative diseases such as Alzheimer's and Traumatic Brain Injury.
What began as a scientific curiosity soon revealed a potentially transformative opportunity. Rather than relying on the cells themselves, these naturally occurring NK cell-derived EVs demonstrated the ability to modulate inflammatory pathways in the brain, opening the door to a new therapeutic approach for neurological disease.
The discovery reinforced a lesson familiar to many great scientists: some of the most important advances emerge not from following a predetermined path, but from recognising the significance of an unexpected result.
Today, Evinco Therapeutics is building on that moment of serendipity, advancing a novel platform designed to harness the power of NK cell-derived EVs to address neuroinflammation and improve outcomes for patients living with devastating neurodegenerative conditions.
EVINCO COMMITMENT
A focused commitment to progressing Alzheimer’s research through the next stage of funding, licensing, development and trial readiness.
CLINICAL PATHWAY TO MARKET
BREAKTHROUGH > APPROVED THERAPY
15-18 MONTHS
$2M
TARGET
FUNDING
$5M
12 MONTHS
INVESTOR
FUNDING
LIMITED
4-5 YEARS
LIMITED
FUNDING
Our
Leadership
Led by Scientific and Commercial Experience
Evinco brings together scientific leadership, biotech experience and commercial development focus.
The team’s immediate priority is to secure the capital required to progress the next stage of the Alzheimer’s treatment opportunity and position the company for further validation, partnerships and growth.
Professor Alan Trounson
AO MSc, PhD, LLD, FRCOG, FATSE, FAHMS, FRANZCOG
Founder, CEO and Executive Chair
Stem cell biologist, IVF pioneer & former President of the California Institute for Regenerative Medicine. Alan Trounson is Founder and Deputy Chair, Cartherics Pty Ltd, Emeritus Professor Monash University and Distinguished Scientist, Hudson Institute for Medical Research, Clayton, Victoria, Australia.
+61 (0) 427 770 811
Dr Jing Yang
TeeBBiotech (Hons), PhD
Principal Scientist
PhD at Griffith University where he uncovered biological deficits to cell movement in olfactory stem cells from people with schizophrenia. In 2021 he joined Shenzhen Bay Laboratory in China and in 2022, he completed a short R&D stint at a new start-up biotech company in Shenzhen working on early discovery of immunotherapies. In 2023, he returned to Shenzhen Bay Laboratory to work on potent small molecule inhibitors that the target cancer cell cycle and small molecule degraders for misfolded proteins in Alzheimer’s Disease. In late 2024, he returned to Australia to start a scientist role at Cartherics and now with Evinco Therapeutics, working on developing immunotherapies for neurological disorders such as Alzheimer’s Disease.
Dr Richard Boyd
BSc (Hons), PhD
Scientific Consultant
Professor of Immunology, Monash University
Co-founder, Cartherics Pty Ltd
Professor of Immunology at Monash University, Dr Richard Boyd is an expert in the nature and function of the thymus microenvironment for forming T cells from blood stem cells and pioneer of clinical trials to boost the T cell-based immune system in cancer patients through rejuvenation of the thymus.
Dr Andrew French
BAgSc (Hons), PhD
Senior Researcher/Scientific Consultant
Andrew French is a senior biotechnology and translational research executive with more than 30 years of global experience advancing innovative biomedical technologies. His career spans reproductive science, regenerative medicine, cancer and neurodegenerative therapeutics, embryology, fertility, and stem cell applications.
Andrew specialises in guiding programs from early discovery through clinical development, with expertise in research design, biomedical diligence, IP strategy, and commercialisation. He has worked extensively across Australia, New Zealand, Hong Kong, Mainland China, the United States, Singapore, Chile, and Uruguay, building strong cross‑border partnerships and navigating diverse regulatory environments.
As a consultant, Andrew has advised over fifty organisations—including leading hospitals, universities, biotech companies, and government agencies—supporting product development, translational strategy, and technology commercialisation.
Prof Alice Pébay
AMBSc (Psych), PhD
Scientific Consultant Dame Kate Campbell Fellow, University of Melbourne
Prof. Alice Pébay AM earned her PhD in Neurosciences from the Universit Pierre et Marie Curie (Paris) in 2001. Prof. Pébay’s research focuses on using patient-specific pluripotent stem cells to model neurodegenerative diseases of the eye and brain. She has an established track record in generating induced pluripotent stem cells (iPSCs) and differentiating them into various cell types for disease modelling, particularly for conditions affecting the central nervous system and the eye.
Dr Christine Filippis
BSc (Hons), PhD
Communications Director
Christine is an experienced communications specialist with expertise across corporate communications, PR, media, and investor relations. She has worked with clients spanning engineering and infrastructure, sustainability, mining, technology, health, and biotechnology, consistently delivering effective communication strategies.